Nektar Therapeutics – Product Pipeline Review – 2012
Reference Code: GMDHC02204CDB
Publication Date: MAY 2012
Nektar Therapeutics – Product Pipeline Review – 2012 GMDHC02204CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Nektar Therapeutics – Product Pipeline Review
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 5
List of Figures ................................................................................................................................................................................ 6
Nektar Therapeutics Snapshot ........................................................................................................................................................... 7
Nektar Therapeutics Overview ...................................................................................................................................................... 7
Key Information ............................................................................................................................................................................. 7
Key Facts....................................................................................................................................................................................... 7
Nektar Therapeutics – Research and Development Overview ........................................................................................................... 8
Key Therapeutic Areas .................................................................................................................................................................. 8
Nektar Therapeutics – Pipeline Review ............................................................................................................................................ 11
Pipeline Products by Stage of Development ............................................................................................................................... 11
Pipeline Products – Monotherapy ............................................................................................................................................... 12
Pipeline Products – Combination Treatment Modalities .............................................................................................................. 13
Nektar Therapeutics – Pipeline Products Glance ............................................................................................................................. 14
Nektar Therapeutics – Late Stage Pipeline ................................................................................................................................. 14
Phase III Products/Combination Treatment Modalities ........................................................................................................... 14
Nektar Therapeutics Clinical Stage Pipeline Products................................................................................................................. 15
Phase II Products/Combination Treatment Modalities ............................................................................................................ 15
Phase I Products/Combination Treatment Modalities ............................................................................................................. 16
Nektar Therapeutics – Early Stage Pipeline Products ................................................................................................................. 17
Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 17
Discovery Products/Combination Treatment Modalities.......................................................................................................... 18
Nektar Therapeutics – Drug Profiles ................................................................................................................................................ 19
Longer Acting Therapeutic Clotting Proteins ............................................................................................................................... 19
Product Description................................................................................................................................................................. 19
Mechanism of Action ............................................................................................................................................................... 19
R&D Progress ......................................................................................................................................................................... 19
NKTR-063.................................................................................................................................................................................... 20
Product Description................................................................................................................................................................. 20
Mechanism of Action ............................................................................................................................................................... 20
R&D Progress ......................................................................................................................................................................... 20
NKTR-102.................................................................................................................................................................................... 21
Product Description................................................................................................................................................................. 21
Mechanism of Action ............................................................................................................................................................... 21
R&D Progress ......................................................................................................................................................................... 21
NKTR-102 + 5-Fluorouracil.......................................................................................................................................................... 23
Product Description................................................................................................................................................................. 23
Mechanism of Action ............................................................................................................................................................... 23
R&D Progress ......................................................................................................................................................................... 23
NKTR-105.................................................................................................................................................................................... 25
Product Description................................................................................................................................................................. 25
Mechanism of Action ............................................................................................................................................................... 25
Nektar Therapeutics – Product Pipeline Review – 2012 GMDHC02204CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Nektar Therapeutics – Product Pipeline Review
R&D Progress ......................................................................................................................................................................... 25
NKTR-125.................................................................................................................................................................................... 26
Product Description................................................................................................................................................................. 26
Mechanism of Action ............................................................................................................................................................... 26
R&D Progress ......................................................................................................................................................................... 26
NKTR-140.................................................................................................................................................................................... 27
Product Description................................................................................................................................................................. 27
Mechanism of Action ............................................................................................................................................................... 27
R&D Progress ......................................................................................................................................................................... 27
NKTR-171.................................................................................................................................................................................... 28
Product Description................................................................................................................................................................. 28
Mechanism of Action ............................................................................................................................................................... 28
R&D Progress ......................................................................................................................................................................... 28
NKTR-181.................................................................................................................................................................................... 29
Product Description................................................................................................................................................................. 29
Mechanism of Action ............................................................................................................................................................... 29
R&D Progress ......................................................................................................................................................................... 29
NKTR-192.................................................................................................................................................................................... 31
Product Description................................................................................................................................................................. 31
Mechanism of Action ............................................................................................................................................................... 31
R&D Progress ......................................................................................................................................................................... 31
NKTR-194.................................................................................................................................................................................... 32
Product Description................................................................................................................................................................. 32
Mechanism of Action ............................................................................................................................................................... 32
R&D Progress ......................................................................................................................................................................... 32
Nektar Therapeutics – Pipeline Analysis .......................................................................................................................................... 33
Nektar Therapeutics – Pipeline Products by Therapeutic Class .................................................................................................. 33
Nektar Therapeutics – Pipeline Products By Target .................................................................................................................... 35
Nektar Therapeutics – Pipeline Products by Route of Administration.......................................................................................... 36
Nektar Therapeutics – Pipeline Products By Mechanism of Action ............................................................................................. 37
Nektar Therapeutics – Recent Pipeline Updates ............................................................................................................................. 39
Nektar Therapeutics - Dormant Projects .......................................................................................................................................... 43
Nektar Therapeutics - Discontinued Pipeline Products .................................................................................................................... 44
Discontinued Pipeline Product Profiles ........................................................................................................................................ 44
PEG-Alfacon ........................................................................................................................................................................... 44
Nektar Therapeutics – Company Statement..................................................................................................................................... 45
Nektar Therapeutics – Locations And Subsidiaries .......................................................................................................................... 48
Head Office.................................................................................................................................................................................. 48
Other Locations & Subsidiaries ................................................................................................................................................... 48
Nektar Therapeutics, Recent Developments .................................................................................................................................... 49
Nektar Therapeutics- Press Release ........................................................................................................................................... 49
Apr 02, 2012: Nektar Doses First Subjects In Phase I Clinical Study Evaluating NKTR-192 For Treatment Of Acute Pain ... 49
Feb 27, 2012: Nektar Presents Positive Phase I Clinical Data Of NKTR-181 At AAPM Annual Meeting................................ 50
Nektar Therapeutics – Product Pipeline Review – 2012 GMDHC02204CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(3)
Nektar Therapeutics – Product Pipeline Review
Oct 28, 2009: Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients
With Platinum-Resistant Ovarian Cancer ................................................................................................................................ 52
Sep 22, 2009: Nektar Reports NKTR-102 Shows Encouraging Anti-Tumor Activity In Ovarian Cancer In Phase I And
Preclinical Data ....................................................................................................................................................................... 52
Apr 22, 2009: Nektar's NKTR-105 Demonstrates Superior Antitumor Activity And Improved Pharmacokinetics Over
Docetaxel In Preclinical Studies .............................................................................................................................................. 53
Feb 17, 2009: Dosing Begins In Phase I Clinical Study Evaluating NKTR-105 In Cancer Patients With Refractory Solid
Tumors .................................................................................................................................................................................... 54
Jan 13, 2009: Nektar Therapeutics Announces Initiation Of First Patient Dosed In Phase 2 Clinical Trial Of NKTR-102 In
Ovarian Cancer ....................................................................................................................................................................... 55
Financial Deals Landscape .............................................................................................................................................................. 56
Nektar Therapeutics, Deals Summary ......................................................................................................................................... 56
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details .................................................................................................. 58
Venture Financing ....................................................................................................................................................................... 58
Pearl Therapeutics Secures Additional $18 Million In Series A Financing .....................................................................